ERYGEL Drug Patent Profile

« Back to Dashboard

When do Erygel patents expire, and when can generic versions of Erygel launch?

Erygel is a drug marketed by Mylan and is included in one NDA.

The generic ingredient in ERYGEL is erythromycin. There is one drug master file entry for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Erygel

A generic version of ERYGEL was approved as erythromycin by TORRENT on July 6^th, 2020.

Summary for ERYGEL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,740
Drug Prices:	Drug price information for ERYGEL
What excipients (inactive ingredients) are in ERYGEL?	ERYGEL excipients list
DailyMed Link:	ERYGEL at DailyMed

See drug prices for ERYGEL

US Patents and Regulatory Information for ERYGEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	ERYGEL	erythromycin	GEL;TOPICAL	050617-001	Oct 21, 1987		DISCN	Yes	No

ERYGEL Market Dynamics and Financial Trajectory: Erythromycin Topical Gel Patent, FDA and Commercial Analysis

Last updated: November 9, 2026

ERYGEL is a topical 2% erythromycin gel used for acne vulgaris. Its commercial profile is shaped by generic substitution, an old active ingredient, limited differentiation, and declining relevance of branded topical antibiotics. Erythromycin topical gel has no meaningful remaining composition-of-matter exclusivity, no biosimilar exposure, and limited patent-based protection. Public companies do not report ERYGEL revenue separately, so the product’s standalone financial trajectory cannot be quantified from public filings.

What is ERYGEL and how is it regulated?

ERYGEL is a prescription topical gel containing erythromycin USP at a 2% concentration. The product is applied to acne lesions and historically competed with topical clindamycin, benzoyl peroxide combinations, retinoids and other anti-acne therapies.

Attribute	ERYGEL profile
Active ingredient	Erythromycin
Dosage form	Topical gel
Strength	2%
Primary indication	Acne vulgaris
Regulatory pathway	FDA drug approval
Product category	Small-molecule topical prescription drug
Biosimilar risk	None
Generic substitution	High
Market status	Mature, low-differentiation product
Standalone revenue disclosure	Not publicly reported

FDA-approved labeling identifies ERYGEL as a topical erythromycin product for acne treatment. The label describes antibacterial activity against organisms associated with acne and warns against prolonged antibiotic use because of resistance concerns.[1]

What is the FDA status of ERYGEL?

The FDA approved erythromycin topical gel products decades ago. ERYGEL is not a new molecular entity and does not benefit from modern regulatory exclusivity periods associated with recently approved drugs.

FDA regulatory considerations include:

• No new chemical entity exclusivity.
• No biologic exclusivity.
• No biosimilar pathway.
• No relevant pediatric exclusivity identified in the public product history.
• Generic approval is available through the abbreviated new drug application pathway when a sponsor demonstrates pharmaceutical equivalence and bioequivalence or comparable topical performance.
• Product-level availability can vary by manufacturer, wholesaler and pharmacy inventory.

The branded ERYGEL product has had limited visibility in recent commercial channels compared with generic erythromycin gel. Public FDA databases and labeling records should be treated separately from commercial availability because an approved application, a listed product and a product actively marketed in the United States are not always the same.

Is ERYGEL still marketed?

The practical market is predominantly generic. The brand name has limited commercial significance, and public financial disclosures do not identify material current ERYGEL sales.

A product may remain referenced in prescribing systems or historical labeling while having low or intermittent commercial availability. Generic erythromycin topical gel is the relevant competitive product for pricing, prescription volume and pharmacy substitution.

What patents protect ERYGEL?

No commercially meaningful patent barrier is expected to protect ERYGEL today. Erythromycin was discovered and commercialized many decades ago, and the topical gel product entered the market long before the current patent-term regime became relevant to most modern pharmaceutical products.

Patent estate assessment

Patent category	ERYGEL exposure
Composition-of-matter patent	Expired
Basic active-ingredient patent	Expired
Original topical formulation patents	Expired or commercially immaterial
Method-of-use patents	Any historical claims would generally be expired
Manufacturing patents	Potentially relevant only to individual generic suppliers
Orange Book patent barrier	No material current barrier identified
Patent-based launch delay	Low

The commercial risk is therefore regulatory and economic rather than patent-driven. A generic manufacturer does not need to overcome a durable ERYGEL patent estate comparable with those surrounding newer dermatology products.

What is the Orange Book status of ERYGEL?

The FDA Orange Book lists approved drug products and, where applicable, patents and regulatory exclusivities. For a mature erythromycin topical product, the main commercial issue is whether a specific branded application remains active and whether any patent listing remains operative.

No current, commercially significant Orange Book patent protection is generally associated with ERYGEL’s active ingredient or historical topical gel technology. Any abbreviated new drug application sponsor would still need to assess the specific reference-listed drug, product availability and FDA requirements applicable to the formulation.

Because the product is an old topical formulation, Orange Book analysis is less important than:

1. The reference product identified by FDA.
2. The availability of a current reference-listed drug.
3. FDA requirements for topical bioequivalence.
4. Manufacturing economics.
5. Pharmacy substitution and reimbursement.

When did ERYGEL lose exclusivity?

ERYGEL lost any meaningful exclusivity associated with its original approval many years ago. The drug does not have a current exclusivity period capable of supporting premium branded pricing.

The relevant timeline is:

Period	Commercial implication
Original approval era	Branded topical erythromycin entered the acne market
Patent expiry period	Generic entry became legally available
Generic expansion	Price competition increased and brand differentiation weakened
Current market	Generic erythromycin products dominate practical substitution

The absence of active exclusivity means that a competitor can enter without negotiating a brand settlement, waiting for a patent expiry or preparing a Paragraph IV challenge against a significant patent estate.

Are there Paragraph IV challenges to ERYGEL?

Paragraph IV litigation is unlikely to be a major current issue for ERYGEL. Paragraph IV certifications are used when an ANDA applicant asserts that a listed patent is invalid, unenforceable or not infringed. That mechanism has limited relevance when the reference product has no commercially important unexpired patent protection.

Historical ANDA activity may have involved certifications to patents that have since expired. Those events do not create a current market barrier.

Which companies are challenging ERYGEL?

No current challenger has a material litigation position comparable with the ANDA disputes surrounding high-value branded drugs. The relevant competitive field consists of generic manufacturers that can market erythromycin topical products under FDA approval, subject to manufacturing, labeling and supply requirements.

Publicly visible companies in the broader generic topical dermatology sector have included manufacturers such as Perrigo, Taro, Glenmark, Teva, Prasco and other FDA-approved suppliers. Their participation in erythromycin topical gel can vary by product, time period and market channel.

What formulations are protected by ERYGEL?

ERYGEL’s formulation is a topical 2% gel. The formulation provides a vehicle for applying erythromycin to acne-affected skin, but it has limited exclusivity value because the active ingredient and general dosage form are longstanding.

Potential formulation variables include:

• Gel vehicle composition.
• Alcohol content.
• Solubilization system.
• Preservatives.
• Viscosity.
• Packaging.
• Stability profile.
• Skin feel and drying characteristics.

These variables can create manufacturing or regulatory differences without creating a durable commercial moat. A generic sponsor may need to match the reference product’s qualitative and quantitative attributes or establish an alternative basis for approval.

How strong is the ERYGEL formulation patent estate?

The formulation estate is weak from a commercial perspective. Historical formulation claims may have protected specific excipient combinations or manufacturing processes, but their age makes current enforceability unlikely. The primary risks are technical execution and FDA approval, not patent exclusion.

How does ERYGEL compare with competing acne drugs?

ERYGEL competes in a market where treatment guidelines have moved toward limiting topical antibiotic monotherapy. Benzoyl peroxide is often used with topical antibiotics to reduce resistance concerns, while topical retinoids and fixed-dose combinations provide broader maintenance value.

Product class	Main advantage	Main weakness versus ERYGEL
Erythromycin topical gel	Familiar, inexpensive, established use	Resistance concerns and limited differentiation
Clindamycin topical products	Strong historical acne utilization	Also subject to antibiotic-resistance concerns
Benzoyl peroxide	Non-antibiotic antibacterial activity	Irritation and bleaching of fabrics
Topical retinoids	Comedolytic and maintenance role	Irritation and slower tolerability adaptation
Fixed antibiotic combinations	Combination efficacy and convenience	Higher cost and more complex product economics
Oral antibiotics	Useful for broader inflammatory disease	Systemic exposure and stewardship concerns
Newer branded topicals	Differentiated delivery or mechanism	Higher price and payer-management risk

ERYGEL’s main advantage is low development risk and a familiar therapeutic category. Its disadvantages are low pricing power, generic competition and reduced physician preference for antibiotic monotherapy.

What is the market size and revenue exposure for ERYGEL?

No reliable public source reports ERYGEL revenue as a standalone product. Manufacturer filings generally aggregate products within broader segments such as pharmaceuticals, dermatology or generic medicines.

The product’s financial trajectory can therefore be characterized qualitatively:

1. Initial branded commercialization generated higher unit economics.
2. Generic entry compressed price and shifted volume toward multiple suppliers.
3. Prescribing moved toward newer topical antibiotics, retinoids and combination products.
4. Current revenue is likely distributed across generic suppliers rather than concentrated in a branded franchise.
5. Any individual supplier’s ERYGEL revenue is likely immaterial to a diversified pharmaceutical company.

The product’s value is more likely to arise from portfolio breadth, manufacturing utilization and pharmacy-channel access than from brand equity.

What factors drive ERYGEL revenue?

Revenue is determined by:

• Generic unit price.
• Number of active suppliers.
• Insurance reimbursement.
• Retail and mail-order formulary placement.
• Acne prescription volume.
• Availability of alternative topical antibiotics.
• Dermatology prescribing patterns.
• Wholesaler stocking.
• Supply interruptions.
• FDA manufacturing compliance.

Price erosion is the dominant long-term force. Unit demand can remain stable while manufacturer revenue declines because average selling prices fall.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are modest but not zero. A supplier must maintain compliant facilities, demonstrate consistent product quality and meet FDA requirements for topical products.

Operational barriers include:

• Control of gel viscosity and homogeneity.
• Microbial limits.
• Stability in the commercial container.
• Consistent erythromycin potency.
• Packaging compatibility.
• Batch release testing.
• Reliable supply of active pharmaceutical ingredient.
• FDA inspection compliance.

These barriers can cause temporary supply concentration, but they do not provide durable market exclusivity. A manufacturing disruption can raise short-term prices or create wholesaler shortages without improving the underlying patent position.

What generic launch scenarios exist for ERYGEL?

Base case: continued low-price generic supply

Multiple approved or historically approved suppliers continue to compete, with low pricing and limited commercial investment. The brand remains marginal.

Upside case: temporary supply tightening

A manufacturing suspension, API shortage or supplier exit reduces available inventory. Remaining manufacturers may gain short-term volume and pricing leverage.

Downside case: further therapeutic substitution

Prescribers shift further toward benzoyl peroxide combinations, topical retinoids and non-antibiotic products. Erythromycin gel prescriptions decline, reducing the market available to generic suppliers.

Launch risk for a new entrant

A new generic entrant would face low regulatory and patent risk but weak commercial returns. The principal challenge would be securing adequate volume in a commoditized market. A supplier would need cost-efficient manufacturing, dependable distribution and a differentiated supply position to justify development expense.

What patent litigation and settlement agreements affect ERYGEL?

No current major patent litigation or settlement agreement is central to ERYGEL’s commercial outlook. The product’s age and generic status reduce the likelihood of high-value litigation.

Unlike recently launched dermatology products, ERYGEL does not appear to have a litigation-driven launch calendar. There is no meaningful need to model:

• 30-month stays from a Paragraph IV suit.
• Authorized-generic settlements.
• First-filer exclusivity as a central market event.
• Patent-term-extension expiry.
• Regulatory exclusivity cliffs.

Any historical disputes should be evaluated as closed or commercially obsolete unless a specific court docket establishes continuing relevance.

How does ERYGEL compare with newer branded dermatology products?

ERYGEL has a weak patent estate but low development cost. Newer branded dermatology products typically have stronger exclusivity and higher revenue per prescription, but they also face greater clinical, regulatory and reimbursement risk.

Factor	ERYGEL	Newer branded dermatology product
Patent strength	Low	Often moderate to strong
Generic entry risk	High and already realized	Usually delayed by patents
Price per prescription	Low	Higher
Clinical differentiation	Limited	Often greater
Manufacturing complexity	Low to moderate	Variable
Payer scrutiny	Driven by low cost	Driven by premium pricing
Revenue visibility	Low standalone disclosure	Often reported within a franchise
Litigation exposure	Low	Potentially substantial

Key Takeaways

• ERYGEL is a mature 2% erythromycin topical gel for acne vulgaris.
• Its original patent and exclusivity advantages have expired or become commercially irrelevant.
• Generic substitution is the central market dynamic.
• No meaningful biosimilar risk exists because ERYGEL is a small-molecule topical drug.
• Paragraph IV litigation and patent settlements are not major current commercial factors.
• The product’s formulation may require technical manufacturing controls but does not provide a durable moat.
• Public companies do not disclose standalone ERYGEL revenue, preventing a reliable product-level financial forecast.
• Long-term revenue pressure comes from generic price erosion, antibiotic-stewardship concerns and substitution by retinoids, benzoyl peroxide combinations and newer acne therapies.
• A new entrant would face low patent risk but limited pricing power and uncertain volume.

FAQs

Is ERYGEL still available by prescription?

Erythromycin topical gel may be available through generic suppliers, while branded ERYGEL availability can vary by market channel and manufacturer status.

Is ERYGEL a generic drug?

ERYGEL is the historical brand name for a prescription erythromycin 2% topical gel. The commercially relevant market is primarily generic erythromycin topical gel.

Can a generic company launch erythromycin gel without a patent license?

Generally, an applicant would not need a license to an expired active-ingredient or historical product patent. It would still need FDA approval and compliant manufacturing.

Does ERYGEL have a 180-day generic exclusivity period?

Any historical first-filer exclusivity would not be expected to create a current commercial barrier for this mature product. The applicable status depends on the specific ANDA and FDA records.

Is erythromycin gel still commercially attractive for pharmaceutical manufacturers?

It can provide portfolio volume or manufacturing utilization, but its standalone attractiveness is limited by low pricing, generic competition and reduced use of topical antibiotic monotherapy.

References

1. U.S. Food and Drug Administration. (n.d.). ERYGEL- erythromycin gel prescribing information. FDA labeling database.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
4. American Academy of Dermatology. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.
5. DailyMed. (n.d.). Erythromycin topical gel drug labeling. National Library of Medicine.